Nyxoah Lowers 2026 Revenue Guidance Despite 19% Q3 Sequential Growth
Medical technology firm Nyxoah SA (EURONEXT:NYXH) reported preliminary global net revenue of approximately €9.2 million for the third quarter of 2026, representing a 19% sequential increase over the second quarter. Growth was led by the U.S. market, where net revenue rose 29% sequentially to roughly €6.7 million. Despite the quarter-over-quarter expansion, the company lowered its full-year 2026 revenue guidance to between €33 million and €35 million, down from its prior outlook of €36 million to €40 million.
The guidance revision highlights a slower-than-anticipated commercial ramp for the Genio obstructive sleep apnea treatment system as medical centers build experience with the technology. However, commercial adoption metrics showed steady progress during the quarter, with 80 new surgeons trained and 53 new high-volume accounts activated in the U.S., bringing totals to 342 trained surgeons and 233 active accounts. The company ended the quarter with approximately €77.0 million in cash, cash equivalents, and financial assets as of September 30, 2026.
Investors and healthcare market observers will be watching the ongoing regulatory review of Nyxoah's premarket approval supplement submitted to the U.S. Food and Drug Administration to expand Genio's indications to Complete Concentric Collapse patients. Management expects continuing sequential revenue growth in the fourth quarter of 2026 while finalizing complete third-quarter financial results.
Key points
- Nyxoah SA generated preliminary third-quarter 2026 global net revenue of €9.2 million, up 19% sequentially from the second quarter.
- U.S. net revenue reached €6.7 million in the third quarter, representing 29% sequential growth over the prior quarter.
- Full-year 2026 global net revenue guidance was reduced to a range of €33 million to €35 million from the previous €36 million to €40 million.
- Cash, cash equivalents, and financial assets totaled approximately €77.0 million as of September 30, 2026.
- The company submitted a premarket approval supplement to the FDA to expand its Genio system indication to Complete Concentric Collapse patients.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What was Nyxoah's revenue for the third quarter of 2026?
Preliminary global net revenue was approximately €9.2 million for the third quarter of 2026, driven by €6.7 million in U.S. net revenue.
Why did Nyxoah adjust its 2026 revenue guidance?
Nyxoah adjusted its full-year guidance to between €33 million and €35 million because the adoption ramp in U.S. sales reflects physicians and centers building initial experience with the Genio technology.
What regulatory progress did Nyxoah make with the FDA?
Nyxoah submitted a premarket approval supplement to the FDA under Breakthrough Device Designation to expand the Genio system's U.S. indication to Complete Concentric Collapse patients.